The Role of Clinical Laboratory Biomarkers in the Early Detection and Prognosis of Sepsis
DOI:
https://doi.org/10.22399/ijcesen.4570Keywords:
Sepsis, biomarkers, early detection, prognosis, procalcitonin, lactate, interleukin-6Abstract
Sepsis, a life-threatening condition resulting from the body's extreme response to infection, requires rapid identification and management to improve patient outcomes. Clinical laboratory biomarkers play a crucial role in the early detection of sepsis by providing valuable diagnostic information. Traditional markers such as white blood cell count and C-reactive protein (CRP) are often supplemented by more specific biomarkers, such as procalcitonin (PCT) and lactate levels, which can indicate an inflammatory response and tissue hypoperfusion, respectively. The timely identification of these biomarkers can aid clinicians in differentiating sepsis from other inflammatory conditions and guide therapy decisions, ultimately improving the chances of survival. In addition to aiding in diagnosis, biomarkers also hold significant promise in prognostication for sepsis patients. Elevated levels of specific biomarkers can indicate the severity of the condition and help stratify patients based on their risk of developing septic shock or multi-organ failure. For instance, biomarkers like interleukin-6 (IL-6) and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) have been studied for their predictive validity in assessing the severity of sepsis. Monitoring these biomarkers over time can provide insights into a patient’s response to treatment, allowing for timely alterations in therapeutic strategies. As research continues to uncover novel biomarkers and refine existing ones, their integration into clinical practice is poised to enhance our approach to sepsis management, ultimately leading to better outcomes for affected individuals.
References
[1] Starr MC, Charlton JR, Guillet R. Neonatal Kidney Collaborative, Advances in Neonatal Acute Kidney Injury. Pediatrics. 2021;148(5). doi: 10.1542/peds.2021-051220.
[2] Toro-Huamanchumo CJ, Cabanillas-Ramirez C, Quispe-Vicuna C, et al. Mean Platelet Volume in Neonatal Sepsis: meta-Analysis of Observational Studies. Children. 2022;9(12):548.
[3] Benitz WE, Achten NB. Technical assessment of the neonatal early-onset sepsis risk calculator. Lancet Infect Dis. 2021;21(5):e134–e140. doi: 10.1016/S1473-3099(20)30490-4.
[4] Stocker M, van Herk W, El Helou S, et al. C-Reactive Protein, Procalcitonin, and White Blood Count to Rule Out Neonatal Early-onset Sepsis Within 36 Hours: a Secondary Analysis of the Neonatal Procalcitonin Intervention Study. Clin Infect Dis. 2021;73(2):e383–e390. doi: 10.1093/cid/ciaa876.
[5] Vardon-Bounes F, Ruiz S, Gratacap MP, Garcia C, Payrastre B, Minville V. Platelets Are Critical Key Players in Sepsis. Int J Mol Sci. 2019;20(14):3494. doi: 10.3390/ijms20143494.
[6] Newman TB, Puopolo KM, Wi S, Draper D, Escobar GJ. Interpreting complete blood counts soon after birth in newborns at risk for sepsis. Pediatrics. 2010;126(5):903–909. doi: 10.1542/peds.2010-0935.
[7] Panda SK, Nayak MK, Thangaraj J, Das P, Pugalia R. Platelet parameters as a diagnostic marker in early diagnosis of neonatal sepsis- Seeking newer answers for older problems. J Family Med Prim Care. 2022;11(5):1748–1754. doi: 10.4103/jfmpc.jfmpc_1271_21.
[8] t.S.o.P.C.M.A. Subspecialty Group of Neonatology, N.S.C.M.D.A. Professional Committee of Infectious Diseases, [Expert consensus on the diagnosis and management of neonatal sepsis (version 2019)]. Zhonghua Er Ke Za Zhi. 2019;57(4):252–257. doi: 10.3760/cma.j.issn.0578-1310.2019.04.005.
[9] Woznica EA, Inglot M, Woznica RK, Lysenko L. Liver dysfunction in sepsis. Adv Clin Exp Med. 2018;27(4):547–551. doi: 10.17219/acem/68363.
[10] Shane AL, Sanchez PJ, Stoll BJ. Neonatal sepsis. Lancet. 2017;390(10104):1770–1780. doi: 10.1016/S0140-6736(17)31002-4.
[11] Mao S, Zang D, Wu L, Shi W, Wang X. Diagnostic and Prognostic Value of Red Blood Cell Distribution Width in Children with Respiratory Tract Infections. Clin Lab. 2019;65(5). doi: 10.7754/Clin.Lab.2018.181041.
[12] Korniluk A, Koper-Lenkiewicz OM, Kaminska J, Kemona H, Dymicka-Piekarska V. Mean Platelet Volume (MPV): new Perspectives for an Old Marker in the Course and Prognosis of Inflammatory Conditions. Mediators Inflamm. 2019;2019:9213074. doi: 10.1155/2019/9213074.
[13] Ellahony DM, El-Mekkawy MS, Farag MM. A Study of Red Cell Distribution Width in Neonatal Sepsis. Pediatr Emerg Care. 2020;36(8):378–383. doi: 10.1097/PEC.0000000000001319.
[14] Baker AH, Leland SB, Freiman E, Herigon JC, Eisenberg MA. Characteristics and Outcomes of Culture-Positive and Culture-Negative Pediatric Sepsis. J Pediatr. 2023;263:113718. doi: 10.1016/j.jpeds.2023.113718.
[15] Iroh Tam PY, Bendel CM. Diagnostics for neonatal sepsis: current approaches and future directions. Pediatr Res. 2017;82(4):574–583. doi: 10.1038/pr.2017.134.
[16] Glaser MA, Hughes LM, Jnah A, Newberry D. Neonatal Sepsis: a Review of Pathophysiology and Current Management Strategies. Adv Neonatal Care. 2021;21(1):49–60. doi: 10.1097/ANC.0000000000000769.
[17] Cai N, Chen ZQ, Tao M, Fan WT, Liao W. Mean platelet volume and red blood cell distribution width is associated with prognosis in premature neonates with sepsis. Open Medicine. 2021;16(1):1175–1181. doi: 10.1515/med-2021-0323.
[18] Sahu P, Raj Stanly EA, Simon Lewis LE, Prabhu K, Rao M, Kunhikatta V. Prediction modelling in the early detection of neonatal sepsis. World J Pediatr. 2022;18(3):160–175. doi: 10.1007/s12519-021-00505-1.
[19] Peerapornratana S, Manrique-Caballero CL, Gomez H, Kellum JA. Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment. Kidney Int. 2019;96(5):1083–1099. doi: 10.1016/j.kint.2019.05.026.
[20] Friedman N, Yochpaz S, Zirkin S, Herzlich J, Marom R. C-reactive protein and the neonatal early-onset sepsis calculator for the diagnosis of neonatal sepsis. Eur J Clin Microbiol Infect Dis. 2021;40(6):1227–1234. doi: 10.1007/s10096-021-04156-y.
[21] Ng WW, Lam SM, Yan WW, Shum HP, MLR, NLR, PLR and RDW to predict outcome and differentiate between viral and bacterial pneumonia in the intensive care unit. Sci Rep. 2022;12(1):15974. doi: 10.1038/s41598-022-20385-3.
[22] Nannan Panday RS, Lammers EMJ, Alam N, Nanayakkara PWB. An overview of positive cultures and clinical outcomes in septic patients: a sub-analysis of the Prehospital Antibiotics Against Sepsis (PHANTASi) trial. Crit Care. 2019;23(1):182. doi: 10.1186/s13054-019-2431-8.
[23] Wen Y, Parikh CR. Current concepts and advances in biomarkers of acute kidney injury. Crit Rev Clin Lab Sci. 2021;58(5):354–368. doi: 10.1080/10408363.2021.1879000.
[24] Scherlinger M, Richez C, Tsokos GC, Boilard E, Blanco P. The role of platelets in immune-mediated inflammatory diseases. Nat Rev Immunol. 2023;1–16.
[25] Cantey JB, Lee JH. Biomarkers for the Diagnosis of Neonatal Sepsis. Clin Perinatol. 2021;48(2):215–227. doi: 10.1016/j.clp.2021.03.012.
[26] Schupp T, Weidner K, Rusnak J, et al. Diagnostic and prognostic role of platelets in patients with sepsis and septic shock. Platelets. 2023;34(1):2131753. doi: 10.1080/09537104.2022.2131753.
[27] O’Reilly D, Murphy CA, Drew R, El-Khuffash A, Maguire PB, Ainle FN. Platelets in pediatric and neonatal sepsis: novel mediators of the inflammatory cascade. Pediatr Res. 2022;91(2):359–367. doi: 10.1038/s41390-021-01715-z.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 International Journal of Computational and Experimental Science and Engineering
This work is licensed under a Creative Commons Attribution 4.0 International License.
